OncoMatch/Clinical Trials/NCT03726359
Phase I Study of Fractionated Stereotactic Radiation Therapy
Is NCT03726359 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for brain metastases.
There is a lack of prospective trial data and consensus guidelines describing the use of Fractionated Stereotactic Radiation Therapy (FSRT) in the treatment of brain metastases. There has been no prospective dose escalation study performed to date to determine the maximum tolerated dose (MTD) in patients treated with FSRT. Prescription doses in the series described above ranged from 18 Gy to 42 Gy, delivered in 3 to 12 fractions. The results of this study will be used to plan future Phase II/III studies to determine the efficacy of different dose fractionation schedules of FSRT. The investigator team thus proposes a Phase I study to determine the feasibility and safety of FSRT in patients with brain metastases.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: radiotherapy
Exception: previous treatment of the target lesion with radiotherapy
Previous treatment of the target lesion with radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Montefiore Medical Center · The Bronx, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify